Physician profile
Amitkumar Patel
NPI 1598059826
$1,608.50
in general payments reported to CMS, 2019-2025
21 companies · $69.18 in 2025
The $69.18 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $63.53 · 2021: $79.13 · 2022: $435 · 2023: $339 · 2024: $421 · 2025: $69.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.81 | 2019-2025 | |
| Janssen Biotech, INC. | $218.47 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $157.70 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $118.56 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.14 | 2019-2024 | Xifaxan |
| Conmed Corporation | $77.15 | 2022 | |
| Celgene Corporation | $75.37 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $68.85 | 2020-2023 | Dificid |
| Pfizer INC. | $64.61 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.11 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $52.05 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $42.95 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $33.09 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $25.33 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $25.32 | 2023 | Givlaari |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $20.61 | 2024 | Linx Reflux Management System |
| Echosens North America, INC. | $19.59 | 2024 | Fibroscan |
| Ferring Pharmaceuticals INC. | $17.52 | 2023 | Rebyota |
| Ardelyx, INC. | $15.06 | 2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $13.14 | 2020 | |
| Braintree Laboratories, INC. | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.